Copyright Reports & Markets. All rights reserved.

Global Gene Therapy in Oncology Market 2019 by Company, Regions, Type and Application, Forecast to 2024

Request for Sample of this report
Buy now

Table of Contents

    1 Gene Therapy in Oncology Market Overview

    • 1.1 Product Overview and Scope of Gene Therapy in Oncology
    • 1.2 Classification of Gene Therapy in Oncology by Types
      • 1.2.1 Global Gene Therapy in Oncology Revenue Comparison by Types (2019-2024)
      • 1.2.2 Global Gene Therapy in Oncology Revenue Market Share by Types in 2018
      • 1.2.3 Ex Vivo
      • 1.2.4 In Vivo
    • 1.3 Global Gene Therapy in Oncology Market by Application
      • 1.3.1 Global Gene Therapy in Oncology Market Size and Market Share Comparison by Applications (2014-2024)
      • 1.3.2 Hospitals
      • 1.3.3 Diagnostics Centers
      • 1.3.4 Research Institutes
    • 1.4 Global Gene Therapy in Oncology Market by Regions
      • 1.4.1 Global Gene Therapy in Oncology Market Size (Million USD) Comparison by Regions (2014-2024)
      • 1.4.1 North America (USA, Canada and Mexico) Gene Therapy in Oncology Status and Prospect (2014-2024)
      • 1.4.2 Europe (Germany, France, UK, Russia and Italy) Gene Therapy in Oncology Status and Prospect (2014-2024)
      • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Gene Therapy in Oncology Status and Prospect (2014-2024)
      • 1.4.4 South America (Brazil, Argentina, Colombia) Gene Therapy in Oncology Status and Prospect (2014-2024)
      • 1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Gene Therapy in Oncology Status and Prospect (2014-2024)
    • 1.5 Global Market Size of Gene Therapy in Oncology (2014-2024)

    2 Manufacturers Profiles

    • 2.1 Bristol-Myers Squibb
      • 2.1.1 Business Overview
      • 2.1.2 Gene Therapy in Oncology Type and Applications
        • 2.1.2.1 Product A
        • 2.1.2.2 Product B
      • 2.1.3 Bristol-Myers Squibb Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2017-2018)
    • 2.2 Cold Genesys
      • 2.2.1 Business Overview
      • 2.2.2 Gene Therapy in Oncology Type and Applications
        • 2.2.2.1 Product A
        • 2.2.2.2 Product B
      • 2.2.3 Cold Genesys Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2017-2018)
    • 2.3 Advantagene
      • 2.3.1 Business Overview
      • 2.3.2 Gene Therapy in Oncology Type and Applications
        • 2.3.2.1 Product A
        • 2.3.2.2 Product B
      • 2.3.3 Advantagene Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2017-2018)
    • 2.4 Amgen
      • 2.4.1 Business Overview
      • 2.4.2 Gene Therapy in Oncology Type and Applications
        • 2.4.2.1 Product A
        • 2.4.2.2 Product B
      • 2.4.3 Amgen Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2017-2018)
    • 2.5 AstraZeneca
      • 2.5.1 Business Overview
      • 2.5.2 Gene Therapy in Oncology Type and Applications
        • 2.5.2.1 Product A
        • 2.5.2.2 Product B
      • 2.5.3 AstraZeneca Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2017-2018)
    • 2.6 Bio-Path Holdings
      • 2.6.1 Business Overview
      • 2.6.2 Gene Therapy in Oncology Type and Applications
        • 2.6.2.1 Product A
        • 2.6.2.2 Product B
      • 2.6.3 Bio-Path Holdings Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2017-2018)
    • 2.7 CRISPR Therapeutics
      • 2.7.1 Business Overview
      • 2.7.2 Gene Therapy in Oncology Type and Applications
        • 2.7.2.1 Product A
        • 2.7.2.2 Product B
      • 2.7.3 CRISPR Therapeutics Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2017-2018)
    • 2.8 Editas Medicine
      • 2.8.1 Business Overview
      • 2.8.2 Gene Therapy in Oncology Type and Applications
        • 2.8.2.1 Product A
        • 2.8.2.2 Product B
      • 2.8.3 Editas Medicine Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2017-2018)
    • 2.9 Geron Corp
      • 2.9.1 Business Overview
      • 2.9.2 Gene Therapy in Oncology Type and Applications
        • 2.9.2.1 Product A
        • 2.9.2.2 Product B
      • 2.9.3 Geron Corp Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2017-2018)
    • 2.10 Idera Pharmaceuticals
      • 2.10.1 Business Overview
      • 2.10.2 Gene Therapy in Oncology Type and Applications
        • 2.10.2.1 Product A
        • 2.10.2.2 Product B
      • 2.10.3 Idera Pharmaceuticals Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2017-2018)
    • 2.11 Intellia Therapeutics
      • 2.11.1 Business Overview
      • 2.11.2 Gene Therapy in Oncology Type and Applications
        • 2.11.2.1 Product A
        • 2.11.2.2 Product B
      • 2.11.3 Intellia Therapeutics Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2017-2018)
    • 2.12 Johnson & Johnson
      • 2.12.1 Business Overview
      • 2.12.2 Gene Therapy in Oncology Type and Applications
        • 2.12.2.1 Product A
        • 2.12.2.2 Product B
      • 2.12.3 Johnson & Johnson Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2017-2018)
    • 2.13 Marsala Biotech
      • 2.13.1 Business Overview
      • 2.13.2 Gene Therapy in Oncology Type and Applications
        • 2.13.2.1 Product A
        • 2.13.2.2 Product B
      • 2.13.3 Marsala Biotech Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2017-2018)
    • 2.14 Merck
      • 2.14.1 Business Overview
      • 2.14.2 Gene Therapy in Oncology Type and Applications
        • 2.14.2.1 Product A
        • 2.14.2.2 Product B
      • 2.14.3 Merck Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2017-2018)
    • 2.15 Mologen AG
      • 2.15.1 Business Overview
      • 2.15.2 Gene Therapy in Oncology Type and Applications
        • 2.15.2.1 Product A
        • 2.15.2.2 Product B
      • 2.15.3 Mologen AG Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2017-2018)
    • 2.16 Oncolytics Biotech
      • 2.16.1 Business Overview
      • 2.16.2 Gene Therapy in Oncology Type and Applications
        • 2.16.2.1 Product A
        • 2.16.2.2 Product B
      • 2.16.3 Oncolytics Biotech Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2017-2018)
    • 2.17 Oncosec
      • 2.17.1 Business Overview
      • 2.17.2 Gene Therapy in Oncology Type and Applications
        • 2.17.2.1 Product A
        • 2.17.2.2 Product B
      • 2.17.3 Oncosec Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2017-2018)
    • 2.18 Oncotelic
      • 2.18.1 Business Overview
      • 2.18.2 Gene Therapy in Oncology Type and Applications
        • 2.18.2.1 Product A
        • 2.18.2.2 Product B
      • 2.18.3 Oncotelic Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2017-2018)
    • 2.19 Shenzhen SiBiono GeneTech
      • 2.19.1 Business Overview
      • 2.19.2 Gene Therapy in Oncology Type and Applications
        • 2.19.2.1 Product A
        • 2.19.2.2 Product B
      • 2.19.3 Shenzhen SiBiono GeneTech Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2017-2018)
    • 2.20 Sillajen Biotherapeutics
      • 2.20.1 Business Overview
      • 2.20.2 Gene Therapy in Oncology Type and Applications
        • 2.20.2.1 Product A
        • 2.20.2.2 Product B
      • 2.20.3 Sillajen Biotherapeutics Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2017-2018)
    • 2.21 Tocagen
      • 2.21.1 Business Overview
      • 2.2.2 Gene Therapy in Oncology Type and Applications
        • 2.21.2.1 Product A
        • 2.21.2.2 Product B
      • 2.21.3 Tocagen Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2017-2018)
    • 2.22 UniQure
      • 2.22.1 Business Overview
      • 2.22.2 Gene Therapy in Oncology Type and Applications
        • 2.22.2.1 Product A
        • 2.22.2.2 Product B
      • 2.22.3 UniQure Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2017-2018)
    • 2.23 Ziopharm Oncology
      • 2.23.1 Business Overview
      • 2.23.2 Gene Therapy in Oncology Type and Applications
        • 2.23.2.1 Product A
        • 2.23.2.2 Product B
      • 2.23.3 Ziopharm Oncology Gene Therapy in Oncology Revenue, Gross Margin and Market Share (2017-2018)

    3 Global Gene Therapy in Oncology Market Competition, by Players

    • 3.1 Global Gene Therapy in Oncology Revenue and Share by Players (2014-2019)
    • 3.2 Market Concentration Rate
      • 3.2.1 Top 5 Gene Therapy in Oncology Players Market Share
      • 3.2.2 Top 10 Gene Therapy in Oncology Players Market Share
    • 3.3 Market Competition Trend

    4 Global Gene Therapy in Oncology Market Size by Regions

    • 4.1 Global Gene Therapy in Oncology Revenue and Market Share by Regions
    • 4.2 North America Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)
    • 4.3 Europe Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)
    • 4.4 Asia-Pacific Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)
    • 4.5 South America Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)
    • 4.6 Middle East and Africa Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)

    5 North America Gene Therapy in Oncology Revenue by Countries

    • 5.1 North America Gene Therapy in Oncology Revenue by Countries (2014-2019)
    • 5.2 USA Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)
    • 5.3 Canada Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)
    • 5.4 Mexico Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)

    6 Europe Gene Therapy in Oncology Revenue by Countries

    • 6.1 Europe Gene Therapy in Oncology Revenue by Countries (2014-2019)
    • 6.2 Germany Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)
    • 6.3 UK Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)
    • 6.4 France Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)
    • 6.5 Russia Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)
    • 6.6 Italy Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)

    7 Asia-Pacific Gene Therapy in Oncology Revenue by Countries

    • 7.1 Asia-Pacific Gene Therapy in Oncology Revenue by Countries (2014-2019)
    • 7.2 China Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)
    • 7.3 Japan Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)
    • 7.4 Korea Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)
    • 7.5 India Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)
    • 7.6 Southeast Asia Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)

    8 South America Gene Therapy in Oncology Revenue by Countries

    • 8.1 South America Gene Therapy in Oncology Revenue by Countries (2014-2019)
    • 8.2 Brazil Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)
    • 8.3 Argentina Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)
    • 8.4 Colombia Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)

    9 Middle East and Africa Revenue Gene Therapy in Oncology by Countries

    • 9.1 Middle East and Africa Gene Therapy in Oncology Revenue by Countries (2014-2019)
    • 9.2 Saudi Arabia Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)
    • 9.3 UAE Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)
    • 9.4 Egypt Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)
    • 9.5 Nigeria Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)
    • 9.6 South Africa Gene Therapy in Oncology Revenue and Growth Rate (2014-2019)

    10 Global Gene Therapy in Oncology Market Segment by Type

    • 10.1 Global Gene Therapy in Oncology Revenue and Market Share by Type (2014-2019)
    • 10.2 Global Gene Therapy in Oncology Market Forecast by Type (2019-2024)
    • 10.3 Ex Vivo Revenue Growth Rate (2014-2024)
    • 10.4 In Vivo Revenue Growth Rate (2014-2024)

    11 Global Gene Therapy in Oncology Market Segment by Application

    • 11.1 Global Gene Therapy in Oncology Revenue Market Share by Application (2014-2019)
    • 11.2 Gene Therapy in Oncology Market Forecast by Application (2019-2024)
    • 11.3 Hospitals Revenue Growth (2014-2019)
    • 11.4 Diagnostics Centers Revenue Growth (2014-2019)
    • 11.5 Research Institutes Revenue Growth (2014-2019)

    12 Global Gene Therapy in Oncology Market Size Forecast (2019-2024)

    • 12.1 Global Gene Therapy in Oncology Market Size Forecast (2019-2024)
    • 12.2 Global Gene Therapy in Oncology Market Forecast by Regions (2019-2024)
    • 12.3 North America Gene Therapy in Oncology Revenue Market Forecast (2019-2024)
    • 12.4 Europe Gene Therapy in Oncology Revenue Market Forecast (2019-2024)
    • 12.5 Asia-Pacific Gene Therapy in Oncology Revenue Market Forecast (2019-2024)
    • 12.6 South America Gene Therapy in Oncology Revenue Market Forecast (2019-2024)
    • 12.7 Middle East and Africa Gene Therapy in Oncology Revenue Market Forecast (2019-2024)

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Methodology

      Gene therapy refers to any procedure that aims to treat or alleviate a disease by genetically modifying the cell of a patient. 

      Scope of the Report:
      The global Gene Therapy in Oncology market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.
      The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
      North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Gene Therapy in Oncology.
      Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
      This report studies the Gene Therapy in Oncology market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Gene Therapy in Oncology market by product type and applications/end industries.

      Market Segment by Companies, this report covers
      Bristol-Myers Squibb
      Cold Genesys
      Advantagene
      Amgen
      AstraZeneca
      Bio-Path Holdings
      CRISPR Therapeutics
      Editas Medicine
      Geron Corp
      Idera Pharmaceuticals
      Intellia Therapeutics
      Johnson & Johnson
      Marsala Biotech
      Merck
      Mologen AG
      Oncolytics Biotech
      Oncosec
      Oncotelic
      Shenzhen SiBiono GeneTech
      Sillajen Biotherapeutics
      Tocagen
      UniQure
      Ziopharm Oncology

      Market Segment by Regions, regional analysis covers
      North America (United States, Canada and Mexico)
      Europe (Germany, France, UK, Russia and Italy)
      Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
      South America (Brazil, Argentina, Colombia)
      Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

      Market Segment by Type, covers
      Ex Vivo
      In Vivo

      Market Segment by Applications, can be divided into
      Hospitals
      Diagnostics Centers
      Research Institutes

      Buy now